Inactive Instrument

Highlights Synta Pharmaceuticals Corp. Nasdaq

Equities

US87162T2069

End-of-day quote Nasdaq Other stock markets
- ^USD	-

11/06	Transcript : Madrigal Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:40 AM
06/06	Madrigal Pharmaceuticals Reports Positive Results in New Analysis of Phase 3 Trial of NASH Drug Rezdiffra	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Madrigal Pharmaceuticals Reports Positive Results in New Analysis of Phase 3 Trial of NASH Drug Rezdiffra	06/06	MT
Madrigal Pharmaceuticals, Inc. Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra Presented at the EASL Congress	06/06	CI
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	07/05	MT
Madrigal Pharmaceuticals Q1 Loss Widens; Shares Fall Pre-Bell	07/05	MT
Madrigal Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Madrigal Pharmaceuticals Says Rezdiffra Available in US	09/04	MT
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis	09/04	CI
Madrigal plans $500 million fund raising to prepare for NASH drug launch	19/03	RE
Madrigal commences $500 million public offering of common stock	19/03	RE
Global markets live: Adobe, Ulta Beauty, Intel, Walt Disney, McDonald's...	15/03
Madrigal Shares Leap Premarket on First FDA NASH Green Light	15/03	DJ
Madrigal Pharmaceuticals Wins Accelerated Approval for Rezdiffra From FDA	15/03	DJ
Madrigal Pharmaceuticals, Inc. Announces FDA Approval of Rezdiffra? for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis with Moderate to Advanced Liver Fibrosis	15/03	CI
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis	05/03	CI
Madrigal Pharmaceuticals Q4 Loss Widens	28/02	MT
Madrigal Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02	CI
Madrigal Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
North American Morning Briefing : Stock Futures -2-	27/02	DJ
Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine	08/02	CI
Sagimet's shares hit new high as fatty liver disease drug shows promise in study	22/01	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Synta Pharmaceuticals Corp. Nasdaq

Equities

US87162T2069

Highlights

Filters